What is the Purpose of this Study?
This study focuses on individuals who have been diagnosed with probable Alzheimer’s disease (AD) and have agitation. Agitated behaviors such as irritability and restlessness, physical/verbal aggression, pacing and wandering are major problems in Alzheimer’s patients. The purpose of the study is to evaluate the effectiveness, safety, and tolerability of an investigational drug called AVP-786 for the treatment of agitation in participants with dementia of the Alzheimer’s type. AVP-786 is a combination product of deudextromethorphan hydrobromide, a central nervous system-active agent, and quinidine sulfate. Participants will be randomly assigned to receive either AVP-786 or placebo.
Eligibility
- Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
- Participants with clinically significant, moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment
- Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
- Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer?s type